Puma Biotechnology Inc. (PBYI)

39.37
0.34 0.87
NASDAQ : Health Technology
Prev Close 39.03
Open 38.90
Day Low/High 38.57 / 39.75
52 Wk Low/High 17.60 / 83.15
Volume 674.03K
Avg Volume 1.15M
Exchange NASDAQ
Shares Outstanding 38.50M
Market Cap 1.55B
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

First Week of PBYI February 2017 Options Trading

First Week of PBYI February 2017 Options Trading

Investors in Puma Biotechnology, Inc. saw new options begin trading this week, for the February 2017 expiration.

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Stock Market.

Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)

Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2016 CTRC-AACR San...

Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB272 (neratinib) was presented at the 2016...

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that updated interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib), given as monotherapy and...

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.

CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

The second paragraph, last sentence of the release has changed. The corrected release reads: PUMA BIOTECHNOLOGY INITIATES A MANAGED ACCESS PROGRAM FOR PB272 (NERATINIB) OUTSIDE THE UNITED STATES ...

Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)

Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its lead drug candidate PB272 (neratinib) will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium...

Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug

Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug

Monday's disclosure that Puma is adding a second drug to its diarrhea prophylaxis protocol for neratinib-treated patients once again raises concern that the drug is too toxic to be approved.

Puma Biotechnology Reports Third Quarter 2016 Financial Results

Puma Biotechnology Reports Third Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2016.

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Closes $172 Million Public Offering Of Common Stock

Puma Biotechnology Closes $172 Million Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the closing of an underwritten public offering of 4,312,500 shares of its common stock at a price to the public of $40.

June 2017 Options Now Available For Puma Biotechnology (PBYI)

June 2017 Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the June 2017 expiration.

Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $40.

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) is commencing a secondary public offering of stock.

Puma Biotechnology Announces Proposed Public Offering Of Common Stock

Puma Biotechnology Announces Proposed Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it is commencing an underwritten public offering of $150 million of shares of its common stock.

Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action

Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Puma Biotechnology, Inc.

Biotech Stock Mailbag: Dynavax, Puma, Ariad

Biotech Stock Mailbag: Dynavax, Puma, Ariad

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Puma Biotechnology Shares Leap Forward

Puma Biotechnology Shares Leap Forward

Shares are finally roaring back from big losses in 2014 and 2015.

Why Puma Biotechnology (PBYI) Stock Is Surging Today

Why Puma Biotechnology (PBYI) Stock Is Surging Today

Puma Biotechnology (PBYI) stock was trading sharply higher Tuesday morning after the FDA approved the new drug application for its breast-cancer treatment.

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Cramer says he's still a believer in Salesforce and its CEO, Marc Benioff, despite the last quarter's results.

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Cramer said the market is a ball of confusion and he doesn't blame any investor for sitting on the sidelines a while.

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology, Inc. , where a total volume of 3,028 contracts has been traded thus far today, a contract volume which is representative of approximately 302,800 underlying shares (given that every 1 contract represents 100 underlying shares).

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

TheStreet Quant Rating: D- (Sell)